Bristol Myers Squibb Stock Falls on Report of $400 Billion Merger Talks With AstraZeneca

Bristol Myers Squibb (BMY) shares fell after reports surfaced of merger discussions with AstraZeneca (AZN) that would value the combined entity near $400 billion, creating one of the largest pharmaceutical deals on record. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb carried a $133 billion valuation.

Wall Street's reception to the potential tie-up has turned increasingly skeptical. The deal would rank among the biggest pharma mergers ever executed, yet investor sentiment has soured as details emerge. Bristol Myers' stock decline signals concerns about integration complexity, potential regulatory hurdles, and the premium required to close a transaction of this magnitude.

The $397 billion combined valuation implies AstraZeneca shareholders would command significant control in any merged entity, raising questions about dilution for Bristol Myers investors. The pharma sector has seen mega-mergers stumble on antitrust scrutiny and post-deal execution challenges, adding to caution around this proposition.